A. anti-PPS IgG (µg/ml)
Patient groups PPS14 Day 0 PPS14 Day30 PPS23F Day 0 PPS23F Day30
Group A (CD4>200) 5.24±1.65 14.23±3.16*** 1.84±0.80 4.74±2.24
Group B  (CD4<200) 5.48±1.86 15.68±4.12* 1.00±0.64 1.94±0.66
 
B. anti-PPS IgM(µg/ml)
Patient groups PPS14 Day 0 PPS14 Day30 PPS23F Day 0 PPS23F Day30
Group A (CD4>200) 0.37±0.08 0.57±0.15 0.16±0.03 0.20±0.04
Group B  (CD4<200) 0.21±0.05 0.28±0.07 0.11±0.02 0.14±0.02
C.Opsonophagocytic titers (OPT)
Patient groups Serotype 14 Day 0 Serotype 14 Day30 Serotype 23F Day 0 Serotype 23F Day30
Group A (CD4>200) 3.0±0.39 4380±1159** 5±1 3979±1131**
Group B  (CD4<200) 5±1 1807±1307 6±1 7040±2254*
Data is represented as mean ± standard error of the mean. * indicates significant rise in the post vaccination (day 30) antibody levels, μg/ml (panels A, B) or OPT (panel C) compared to pre-vaccination (day 0) within a group. Pre to post vaccination changes in a single group were compared using paired t-test and between groups were compared usinganalysis of co-variance (ANCOVA).*p<0.05, **p<0.01, ***p<0.001.
Table 2: Serum anti-PPS antibody response post-PPV23 revaccination in long term HAART cohorts.
Goto home»